Delivery of docetaxel using pH-sensitive liposomes based on D-α-tocopheryl poly(2-ethyl-2-oxazoline) succinate: Comparison with PEGylated liposomes

Han, Shu; Sun, Ruiyang; Su, Hua; Lv, Jing; Xu, Huan; Zhang, Di; Fu, Yuanshan

doi:10.1016/j.ajps.2018.07.005

Cited by 19 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our work, the PEG-dia was selected as a cross-linker to decorate the dual redox-responsive HSS nanoparticles via amide formation in the presence of EDC to improve the stability and prolong the circulation time. Additionally, the modification of PEG supplied the nanocarriers with enhanced long-circulating properties . To confirm the chemical cross-linking, PHSS was analyzed by 1 H NMR spectroscopy (Figure S3).…”

Section: Results and Discussionmentioning

confidence: 99%

“…Additionally, the modification of PEG supplied the nanocarriers with enhanced longcirculating properties. 36 To confirm the chemical cross-linking, PHSS was analyzed by 1 H NMR spectroscopy (Figure S3). The characteristic peaks of the PEG backbone at appeared at 3.61− 3.83 ppm, peaks of HA appeared at 2.00 ppm, and the peaks of amide appeared at 7.84 ppm demonstrated the successful crosslinking of PEG-dia on HSS through the amide formation.…”

Section: Synthesis and Characterization Of Hss And Hcsmentioning

confidence: 99%

See 1 more Smart Citation

Reduction/Oxidation-Responsive Hierarchical Nanoparticles with Self-Driven Degradability for Enhanced Tumor Penetration and Precise Chemotherapy

Yin

Gao

Zhang

et al. 2020

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Deep tumor penetration, long blood circulation, rapid drug release, and sufficient stability are the most concerning dilemmas of nano-drug-delivery systems for efficient chemotherapy. Herein, we develop reduction/oxidation-responsive hierarchical nanoparticles co-encapsulating paclitaxel (PTX) and pH-stimulated hyaluronidase (pSH) to surmount the sequential biological barriers for precise cancer therapy. Poly(ethylene glycol) diamine (PEG-dia) is applied to collaboratively cross-link the shell of nanoparticles self-assembled by a hyaluronic acid–stearic acid conjugate linked via a disulfide bond (HA–SS–SA, HSS) to fabricate the hierarchical nanoparticles (PHSS). The PTX and pSH coloaded hierarchical nanoparticles (PTX/pSH-PHSS) enhance the stability in normal physiological conditions and accelerate drug release at tumorous pH, and highly reductive or oxidative environments. Functionalized with PEG and HA, the hierarchical nanoparticles preferentially prolong the circulation time, accumulate at the tumor site, and enter MDA-MB-231 cells via CD44-mediated endocytosis. Within the acidic tumor micro-environment, pSH would be partially reactivated to decompose the dense tumor extracellular matrix for deep tumor penetration. Interestingly, PTX/pSH-PHSS could be degraded apace by the completely activated pSH within endo/lysosomes and the intracellular redox micro-environment to facilitate drug release to produce the highest tumor inhibition (93.71%) in breast cancer models.

show abstract

Section: Results and Discussionmentioning

confidence: 99%

Section: Synthesis and Characterization Of Hss And Hcsmentioning

confidence: 99%

Reduction/Oxidation-Responsive Hierarchical Nanoparticles with Self-Driven Degradability for Enhanced Tumor Penetration and Precise Chemotherapy

Yin

Gao

Zhang

et al. 2020

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…The drug load (DL) and encapsulation efficacy (EE) were measured as previously ( Zhang et al, 2015 ; Han et al, 2019 ; Kou et al, 2020a ). Briefly, a Sephadex G50 column was prepared and used to remove the unloaded free drug by elution.…”

Section: Methodsmentioning

confidence: 99%

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment

Bao

Zheng

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Pancreatic cancer (PC) is one of the most common malignancies and also a leading cause of cancer-related mortality worldwide. Many studies have shown that epidermal growth factor receptor (EGFR) is highly expressed in PC, which provides a potential target for PC treatment. However, EGFR inhibitors use alone was proven ineffective in clinical trials, due to the persistence of cellular feedback mechanisms which foster therapeutic resistance to single targeting of EGFR. Specifically, the signal transducer and activator of transcription 3 (STAT3) is over-activated when receiving an EGFR inhibitor and is believed to be highly involved in the failure and resistance of EGFR inhibitor treatment. Therein, we hypothesized that dual inhibition of EGFR and STAT3 strategy could address the STAT3 induced resistance during EGFR inhibitor treatment. To this end, we tried to develop poly (lactic-co-glycolic acid) (PLGA) nanoparticles to co-load Alantolactone (ALA, a novel STAT3 inhibitor) and Erlotinib (ERL, an EGFR inhibitor) for pancreatic cancer to test our guess. The loading ratio of ALA and ERL was firstly optimized in vitro to achieve a combined cancer-killing effect. Then, the ALA- and ERL-co-loaded nanoparticles (AE@NPs) were successfully prepared and characterized, and the related anticancer effects and cellular uptake of AE@NPs were studied. We also further detailly explored the underlying mechanisms. The results suggested that AE@NPs with uniform particle size and high drug load could induce significant pancreatic cancer cell apoptosis and display an ideal anticancer effect. Mechanism studies showed that AE@NPs inhibited the phosphorylation of both EGFR and STAT3, indicating the dual suppression of these two signaling pathways. Additionally, AE@NPs could also activate the ROS-p38 axis, which is not observed in the single drug treatments. Collectively, the AE@NPs prepared in this study possess great potential for pancreatic cancer treatment by dual suppressing of EGFR and STAT3 pathways and activating ROS-responsive p38 MAPK pathway.

show abstract

“…The drug release patterns of nanoparticles were analyzed using dialysis method. 28 Drugs loaded nanoparticles (3 mL) were sealed in dialysis bags (MWCO 8–14 kDa) and incubated in PBS (100 mL, pH 7.4) containing 0.1% (w/v) Tween 80 at 37°C. At different time points, 300 μL of release medium was replaced by 300 μL of fresh PBS.…”

Section: Methodsmentioning

confidence: 99%

Transferrin-Decorated Protein-Lipid Hybrid Nanoparticle Efficiently Delivers Cisplatin and Docetaxel for Targeted Lung Cancer Treatment

Mao¹,

Zhang²,

Yu³

et al. 2021

DDDT

View full text Add to dashboard Cite

Purpose Non-small cell lung cancer (NSCLC) therapy faces the barriers including drug resistance. A transferrin-functionalized protein-lipid hybrid nanoparticle (PLHN) was designed loading both cisplatin (CIS) and docetaxel (DTX) for the lung cancer treatment. Methods CIS and DTX were loaded into the hybrid nanoparticle and then decorated with transferrin (Tf). The Tf-functionalized protein-lipid hybrid nanoparticle (Tf-CIS/DTX-PLHN) was investigated by determining the release behavior, cytotoxicity in vitro, and anticancer efficiency in vivo. Results Tf-CIS/DTX-PLHN showed a nano-size of 189.5 ± 5.9 nm, and a surface tested to be −16.9 ± 2.1 mV. Tf-CIS/DTX-PLHN exhibited obviously better antitumor ability in vitro and in vivo compared with the non Tf contained CIS and DTX co-loaded lipid nanoparticles (CIS/DTX-LN), single drug loaded nanoparticles, and free drugs. Conclusion Since remarkable enhanced efficiency of Tf and synergistic effect of the drugs, it could inhibit the lung tumor growth and help with the lung cancer treatment.

show abstract

Delivery of docetaxel using pH-sensitive liposomes based on D-α-tocopheryl poly(2-ethyl-2-oxazoline) succinate: Comparison with PEGylated liposomes

Cited by 19 publications

References 43 publications

Reduction/Oxidation-Responsive Hierarchical Nanoparticles with Self-Driven Degradability for Enhanced Tumor Penetration and Precise Chemotherapy

Reduction/Oxidation-Responsive Hierarchical Nanoparticles with Self-Driven Degradability for Enhanced Tumor Penetration and Precise Chemotherapy

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment

Transferrin-Decorated Protein-Lipid Hybrid Nanoparticle Efficiently Delivers Cisplatin and Docetaxel for Targeted Lung Cancer Treatment

Contact Info

Product

Resources

About